A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Vandetanib (Primary) ; Digoxin
- Indications Arrhythmias; Biliary cancer; Breast cancer; Prostate cancer; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Sanofi
- 26 Jul 2012 Actual end date (July 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2012 Actual initiation date (Mar 2012) added as reported by ClinicalTrials.gov.